NL-OMON53492招募中3 期
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica - REDUCE PMR1
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Newly diagnosed PMR (<12 weeks) according to the 2012 EULAR/ACR
- •classification criteria. • Glucocorticoid treatment <= 8 weeks • Glucocorticoid
- •dose equivalent of prednisolone <=30 mg/day.
排除标准
- •Treatment with systemic immunosuppressants (other than GC, MTX, leflunomide
- •and azathioprine) 3 months prior to inclusion
- •(clinical) suspect concomitant giant cell arteritis or other rheumatic
- •inflammatory disease
- •Concomitant conditions that might significantly interfere with evaluation of
- •PMR pain or movement as judged by the investigator
- •Previous hypersensitivity for RTX of contra-indications to RTX
- •Not being able to speak, read or write Dutch
研究者
相似试验
招募中
1 期
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia RheumaticaPolymyalgia rheumaticaEUCTR2022-003127-18-NLSint Maartenskliniek114
招募中
1 期
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia RheumaticaPolymyalgia rheumaticaMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2022-003128-42-NLSint Maartenskliniek174
招募中
3 期
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapsePolymyalgia RheumaticaNL-OMON53470Sint Maartenskliniek174
进行中（未招募）
3 期
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapsePolymyalgia RheumaticaNCT05533164Sint Maartenskliniek174
已完成
3 期
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently DiagnosedPolymyalgia RheumaticaNCT05533125Sint Maartenskliniek114